Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 4.1 %

Shares of BTX opened at $0.33 on Thursday. The stock has a market cap of $19.40 million, a PE ratio of -0.15 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The business has a 50-day simple moving average of $0.52 and a two-hundred day simple moving average of $1.18.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.